Lucas Santos Souza

Lucas Santos Souza

Auto-generated profile, based on publicly available information

Lucas Santos Souza

Universidade de São Paulo. Escola Superior de Agricultura Luiz de Queiroz

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ARAntonio F. Ribeiro
Antonio F. Ribeiro
LSLucas S. Souza
Lucas S. Souza
CACamila F. Almeida
Camila F. Almeida
RIRenata Ishiba
Renata Ishiba
SFStephanie A. Fernandes
Stephanie A. Fernandes
MVMariz Vainzof
Mariz Vainzof
Satellite cells (SCs) are the main muscle stem cells responsible for its regenerative capacity. In muscular dystrophies, however, a failure of the regenerative process results in muscle degeneration and weakness. To analyze the effect of different degrees of muscle degeneration in SCs behavior, we studied adult muscle of the dystrophic strains: DMDmdx, Largemyd, DMDmdx/Largemyd, with variable histopathological alterations. Similar results were observed in the dystrophic models, which maintained normal levels of PAX7 expression, retained the Pax7-positive SCs pool, and their proliferation capacity. Moreover, elevated expression of MYOG, an important myogenic factor, was also observed. The ability to form new fibers was verified by the presence of dMyHC positive regenerating fibers. However, those fibers had incomplete maturation characteristics, such as small and homogenous fiber caliber, which could contribute to their dysfunction. We concluded that dystrophic muscles, independently of their degeneration degree, retain their SCs pool with proliferating and regenerative capacities. Nonetheless, the maturation of these new fibers is incomplete and do not prevent muscle degeneration. Taken together, these results suggest that the improvement of late muscle regeneration should better contribute to therapeutic approaches.

10 January 2020 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
SFStephanie A. Fernandes
Stephanie A. Fernandes
CACamila F. Almeida
Camila F. Almeida
LSLucas S. Souza
Lucas S. Souza
MLMonize Lazar
Monize Lazar
POPaula Onofre-Oliveira
Paula Onofre-Oliveira
MVMariz Vainzof
Mariz Vainzof
X-linked myopathy with excessive autophagy (XMEA) is a genetic disease associated with weakness of the proximal muscles. It is caused by mutations in the VMA21 gene, coding for a chaperone that functions in the vacuolar ATPase (v-ATPase) assembly. Mutations associated with lower content of assembled v-ATPases lead to an increase in lysosomal pH, culminating in partial blockage of macroautophagy, with accumulation of vacuoles of undigested content. Here, we studied a 5-year-old boy affected by XMEA, caused by a small indel in the VMA21 gene. Detection of sarcoplasmic Lc3 (also known as MAP1LC3B)-positive vacuoles in his muscle biopsy confirmed an autophagy defect. To understand how autophagy is regulated in XMEA myogenesis, we used patient-derived muscle cells to evaluate autophagy during in vitro muscle differentiation. An increase in lysosomal pH was observed in the patient's cells, compatible with predicted functional defect of his mutation. Additionally, there was an increase in autophagic flux in XMEA myotubes. Interestingly, we observed that differentiation of XMEA myoblasts was altered, with increased myotube formation observed through a higher fusion index, which was not dependent on lysosomal acidification. Moreover, no variation in the expression of myogenic factors nor the presence of regenerating fibers in the patient's muscle were observed. Myoblast fusion is a tightly regulated process; therefore, the uncontrolled fusion of XMEA myoblasts might generate cells that are not as functional as normal muscle cells. Our data provide new evidence on the reason for predominant muscle involvement in the context of the XMEA phenotype. This article has an associated First Person interview with the first author of the paper.

19 June 2019 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
RIRenata Ishiba
Renata Ishiba
ASAndré Luis F. Santos
André Luis F. Santos
CACamila F. Almeida
Camila F. Almeida
LCLuiz Carlos Caires
Luiz Carlos Caires
ARAntonio F. Ribeiro
Antonio F. Ribeiro
MVMariz Vainzof
Mariz Vainzof

1 November 2021 in Neuromuscular Disorders
Verified
Journal Article
Closed access
JGJuliana Gurgel-Giannetti
Juliana Gurgel-Giannetti
LSLucas Santos Souza
Lucas Santos Souza
GAGuilherme Ferraz Messina de Pádua Andrade
Guilherme Ferraz Messina de Pádua Andrade
MDMaria de Fátima Derlene
Maria de Fátima Derlene
ZMZilda Maria Alves Meira
Zilda Maria Alves Meira
MVMariz Vainzof
Mariz Vainzof

20 January 2025 in Heliyon
Verified
Journal Article
Open access
RSRita Ccs. Santos
Rita Ccs. Santos
LLLarissa Fcdms. Lima
Larissa Fcdms. Lima
PAPâmela V. Andrade
Pâmela V. Andrade
JSJoilson M. Santos
Joilson M. Santos
LGLeonardo Galleni
Leonardo Galleni
HSHelga C.A. Silva
Helga C.A. Silva
Hypermobility is the capacity to perform joint movements in amplitudes greater than normal. Hypermobility is present in nearly 100 % of congenital myopathy central core disease (CCD) patients but is sporadically described in the allelic disease malignant hyperthermia (MH). Our objective was to investigate the frequency/characteristics of hypermobility in MH susceptible patients as compared to a control group, aiming the identification of correlations between hypermobility and demographic/clinical findings in MH patients. We recruited 26 MH patients (MH history, positive in vitro contracture test (IVCT), no muscle weakness, no cores in muscle biopsy) and 23 controls (no MH/myopathy history). Patients/medical records were evaluated for obtaining demographic/clinical data. Hypermobility was assessed in all patients and controls with Bulbena score. Goniometry was performed in a subset of 11 patients and 11 controls. Bulbena score indicative of hypermobility was significantly more frequent in MH than in the control group (50 % versus 13 %, relative risk 2.06 (95%CI 1.27-3.35), chi-square test, p < .01). Goniometric assessment revealed significantly greater range of motion of mostly proximal movements in MH versus control groups. In the MH group, there was no correlation of the Bulbena score with age, sex, clinical complaints of myalgia/cramps, CK levels, IVCT result, or degree of contracture after caffeine or halothane. It is possible that predominantly proximal hypermobility is part of a clinical spectrum associated with RYR1 gene variants, as it was present even when associated muscle weakness was not present. More studies are necessary to measure evolution and long-term impact of hypermobility in MH patients.